loading page

Prevention and treatment of platinum ototoxicity in adults: A systematic review
  • +5
  • Juan Esteban Correa-Morales,
  • Sara Giraldo-Moreno,
  • Nidia Mantilla-Manosalva,
  • Laura Cuellar-Valencia,
  • Lennis Jazmin Bedoya-Muñoz,
  • María Fernanda Iriarte-Aristizábal,
  • Elias Quintero-Muñoz,
  • Andrea Marcela Zuluaga-Liberato
Juan Esteban Correa-Morales
Universidad de la Sabana Facultad de Medicina

Corresponding Author:[email protected]

Author Profile
Sara Giraldo-Moreno
Universidad CES Clinica CES
Author Profile
Nidia Mantilla-Manosalva
Universidad de la Sabana Facultad de Medicina
Author Profile
Laura Cuellar-Valencia
Universidad de la Sabana Facultad de Medicina
Author Profile
Lennis Jazmin Bedoya-Muñoz
Universidad de la Sabana Facultad de Medicina
Author Profile
María Fernanda Iriarte-Aristizábal
Universidad de la Sabana Facultad de Medicina
Author Profile
Elias Quintero-Muñoz
Universidad de la Sabana Facultad de Medicina
Author Profile
Andrea Marcela Zuluaga-Liberato
Instituto Nacional de Cancerologia
Author Profile

Abstract

Background: Ototoxicity is a common disabling side effect of platinum-based chemotherapy. This study aimed to systematically assess the evidence on the management of platinum-induced ototoxicity in adult cancer patients. Methods: Three databases were searched up to November 1, 2022. Original studies were included if they reported on a pharmacologic or non-pharmacologic intervention to prevent or treat platinum ototoxicity in adults. The articles’ quality was assessed with two grading scales. Results: Eighteen randomized controlled trials and five quasi-experimental studies with 1673 patients were analyzed. Eleven interventions were identified, nine pharmacological and two non-pharmacological. Six of the interventions (sodium thiosulfate, corticoids, sertraline, statins, multivitamins, and D-methionine) showed mild benefit preventing cisplatin-induced ototoxicity. The data must be carefully analyzed due to the low quality and underreporting of side effects. Conclusions: Current interventions have mild benefits preventing cisplatin-induced ototoxicity in adult cancer patients. High-quality research is required to clarify the significance of these findings.
11 Feb 2023Submitted to Clinical Otolaryngology
21 Feb 2023Submission Checks Completed
21 Feb 2023Assigned to Editor
07 Mar 2023Reviewer(s) Assigned
20 May 2023Review(s) Completed, Editorial Evaluation Pending
25 Jun 2023Editorial Decision: Revise Major
29 Aug 20231st Revision Received
05 Sep 2023Submission Checks Completed
05 Sep 2023Assigned to Editor
08 Sep 2023Reviewer(s) Assigned
10 Sep 2023Review(s) Completed, Editorial Evaluation Pending
23 Sep 2023Editorial Decision: Accept